Nuwellis Overhauls Board with New Financial and Operational Expertise
Event summary
- Nuwellis appointed Katharyn Field and Mika Grasso to its board of directors on January 21, 2026.
- Field brings CEO experience in medical technology and biotech, while Grasso offers investment management expertise.
- Dave McDonald, Mike McCormick, and Dr. Maria Costanzo resigned from the board effective January 21, 2026.
- Resignations were not due to disagreements with Nuwellis' operations or policies.
The big picture
Nuwellis' board refresh signals a shift towards stronger financial and operational governance, aligning with broader trends in medical technology companies seeking to enhance strategic agility. The appointments come as the company continues to focus on advancing precision fluid management technologies across critical care settings. The move may also reflect preparations for potential scaling or strategic pivots in response to evolving market dynamics.
What we're watching
- Strategic Direction
- How the new board members will influence Nuwellis' precision cardiorenal care strategy.
- Financial Oversight
- Whether Mika Grasso's investment background will drive more aggressive financial growth initiatives.
- Operational Efficiency
- The pace at which Katharyn Field's operational expertise translates into streamlined processes.
Our editorial coverage: